Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inverse Psoriasiform Eruption During Pembrolizumab Therapy for Metastatic Melanoma.

× No keyword cloud information.

15 in total

Review 1. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors.

Authors: Subashini Sharon Gnanendran; Lauren Maree Turner; James Austin Miller; Shelley Ji Eun Hwang; Andrew Charles Miller
Journal: Curr Treat Options Oncol Date: 2020-03-19

Review 2. Cutaneous Complications of Targeted Melanoma Therapy.

Authors: Emily de Golian; Bernice Y Kwong; Susan M Swetter; Silvina B Pugliese
Journal: Curr Treat Options Oncol Date: 2016-11

3. Ixekizumab for the treatment of erythrodermic psoriasis triggered by durvalumab-tremelimumab in a cancer patient.

Authors: Arrieta Vinaixa Aranzazu; Víctor Morillas-Lahuerta; María Blanco De Tord; José-Manuel Carrascosa Carrillo
Journal: Eur J Dermatol Date: 2021-08-26 Impact factor: 2.805

4. Immune checkpoint inhibitors unleash pathogenic immune responses against the microbiota.

Authors: Zishuo Ian Hu; Verena M Link; Djalma S Lima-Junior; Jérémie Delaleu; Nicolas Bouladoux; Seong-Ji Han; Nicholas Collins; Yasmine Belkaid
Journal: Proc Natl Acad Sci U S A Date: 2022-06-21 Impact factor: 12.779

Review 5. Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

Authors: Samantha R Ellis; Aren T Vierra; Jillian W Millsop; Mario E Lacouture; Maija Kiuru
Journal: J Am Acad Dermatol Date: 2020-04-29 Impact factor: 11.527

Review 6. Immune checkpoint inhibitor-related dermatologic adverse events.

Authors: Amaris N Geisler; Gregory S Phillips; Dulce M Barrios; Jennifer Wu; Donald Y M Leung; Andrea P Moy; Jeffrey A Kern; Mario E Lacouture
Journal: J Am Acad Dermatol Date: 2020-05-23 Impact factor: 11.527

7. Inverse lichenoid drug eruption associated with nivolumab.

Authors: Lauren M Guggina; Daniel A Yanes; Jennifer N Choi
Journal: JAAD Case Rep Date: 2016-12-22

8. Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.

Authors: Alessio Cortellini; Alessandro Parisi; Maria Concetta Fargnoli; Katia Cannita; Azzurra Irelli; Giampiero Porzio; Claudio Martinazzo; Corrado Ficorella
Journal: Case Rep Oncol Med Date: 2018-03-08

Review 9. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events.

Authors: Esmée P Hoefsmit; Elisa A Rozeman; John B A G Haanen; Christian U Blank
Journal: ESMO Open Date: 2019-07-21

10. Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review.

Authors: Marlies De Bock; Eva Hulstaert; Vibeke Kruse; Lieve Brochez
Journal: Case Rep Dermatol Date: 2018-08-09